RIBOLIFE-B (06938) intends to acquire the remaining 49.71% equity interest in Ribocure Pharmaceuticals AB.

RIBOLIFE-B (06938) announces that on October 16, 2026, the Company entered into a share exchange agreement with the minority shareholders, pursuant to which, subject to and in accordance with the terms and conditions of the share exchange agreement, the Company has conditionally agreed to acquire, and the minority shareholders have severally and conditionally agreed to sell, the target shares (representing in aggregate 49.71% of the total number of issued shares of the target company), such that the Company will hold the entire equity interest in the target company. As at the date of this announcement, the Company holds approximately 50.29% of the total number of issued shares of the target company. Upon completion, the target company will become a wholly-owned subsidiary of the Company. The transaction will be effected through a share swap between the Company and the minority shareholders. For each target share transferred to the Company by each minority shareholder in respect of the transaction, 15 consideration shares will be issued. The 14,087,000 consideration shares represent in aggregate approximately 8.26% of the total number of issued shares as at the date of this announcement, and in aggregate approximately 7.63% of the total number of issued shares as enlarged by the consideration shares (assuming that there is no other change in the total number of issued shares from the date of this announcement to the period of allotment and issue of the consideration shares). The target company, Ribocure Pharmaceuticals AB, is a clinical-stage biotechnology company organized under Swedish law in February 2022. As the Company's international R&D center, the target company is principally engaged in global clinical development and translational research of oligonucleotide therapeutics, with a particular focus on siRNA drugs targeting cardiovascular, metabolic, hepatic, renal and neurodegenerative diseases. The target company currently has five drug discovery and preclinical-stage projects, of which two have advanced to near clinical filing stage and two major out-licensing collaboration projects.